S80039
具體成交價(jià)以合同協(xié)議為準(zhǔn)
- 公司名稱 上海源葉生物科技有限公司
- 品牌
- 型號(hào)
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2024/7/3 19:11:12
- 訪問(wèn)次數(shù) 111
聯(lián)系方式：何小姐15921386130 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息，謝謝!
生物試劑,ELISA試劑盒,對(duì)照品,標(biāo)準(zhǔn)品,培養(yǎng)基,透析袋,病理科耗材,實(shí)驗(yàn)室耗材
- 提示：詳情請(qǐng)下載說(shuō)明書(shū),。
- 產(chǎn)品描述： Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity
- 靶點(diǎn)： PI3Kα：0.5 nM (IC50),；PI3Kβ：3.7 nM (IC50)；PI3Kδ：0.7 nM (IC50),；PI3Kγ：6.4 nM (IC50),；mTOR：45 nM (IC50)
- 體內(nèi)研究： Copanlisib (BAY 80-6946; 0.5-6 mg/kg; intravenous injection; every second day, every third day; for 60 days; athymic nude rats) treatment displays robust antitumor activity in the rat KPL4 tumor xenograft model
- 參考文獻(xiàn)：
1. Liu N, et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Mol Cancer Ther. 2013 Nov;12(11):2319-30.
- 溶解度： 1M HCl : 100 mg/mL (208.11 mM; Need ultrasonic)
- 保存條件： -20℃
- 配置溶液濃度參考：
1mg 5mg 10mg 1 mM 2.081 ml 10.405 ml 20.811 ml 5 mM 0.416 ml 2.081 ml 4.162 ml 10 mM 0.208 ml 1.041 ml 2.081 ml 50 mM 0.042 ml 0.208 ml 0.416 ml
- 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的性,，僅供客戶參考交流研究之用,。
采購(gòu)中心
化工儀器網(wǎng)